Skip to main content

Advertisement

Table 1 Demographic and baseline characteristics

From: Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials

  Dabigatran 220 mg Enoxaparin 40 mg
(n = 2,156) (n = 2,157)
Number of treated patients 2,156 2,157
 Age, yr 63 ± 11 63 ± 11
 Females, n (%) 1177 (54.6) 1152 (53.4)
 Weight, kg 79 ± 16 79 ± 16
 Body mass indexa 27.8 ± 4.7 27.6 ± 4.6
 Previous VTE, n (%) 65 (3.0) 54 (2.5)
 Creatinine clearanceb, mL/min 92 ± 31 93 ± 31
Racec, n (%)   
 White 2,051 (95.1) 2,052 (95.1)
 Asian 96 (4.4) 88 (4.1)
 Black 5 (0.2) 12 (0.6)
 Other 4 (0.2) 5 (0.2)
Geographical region, n (%)   
 Western Europe 1,282 (59.5) 1,291 (59.9)
 Central Europe 474 (22.0) 470 (21.8)
 North America 170 (7.9) 168 (7.8)
 India 91 (9.0) 88 (4.1)
 Australia/New Zealand/South Africa 139 (6.4) 140 (6.5)
Patients treated and operated, n (%) 2,138 (99.2) 2,134 (98.9)
Anesthesiad, n (%)   
 General alone 525 (24.4) 503 (22.3)
 Neuraxial alonee 1,461 (67.8) 1,486 (65.8)
 Combinationf 149 (6.9) 144 (6.4)
Mean duration of surgery ± SD, min 85.4 ± 30.2 85. ±30.4
Study treatment   
 Mean time to first subcutaneous injectiong,h in relation to surgery, hr –15.6 ± 20.7 –15.2 ± 13.5
 Mean time to first oral dose postsurgeryh, hr 3.1 ± 2.6 3.2 ± 2.7g
 Median (range) duration of hospital stayi, d 8.5 (3–51) 8.5 (3–26)
 Median (range) treatment duration, d 31.6 (1–89) 31.7 (1–49)
  1. Data are given as mean ± SD except where indicated
  2. SD standard deviation, VTE Venous thromboembolism
  3. aBody mass index was defined as weight in kilograms divided by square of height in meters; bCreatinine clearance rates were calculated using the Cockcroft–Gault formula; cAs reported by the investigator; dPatients may have had more than one type of anesthetic; eIncludes spinal and epidural anesthesia; fPeripheral nerve block plus general or neuraxial anesthesia; g26 patients in RE-NOVATE II group received their first dose postsurgery; hIncludes both active treatment and placebo; iTime from surgery until day of discharge, data available in RE-NOVATE for 1,136 and 1,140 patients, respectively